To Evaluate a Phase Ia/Ib Clinical Study of EG017 in Patients With Advanced Breast Cancer.
Status:
Not yet recruiting
Trial end date:
2026-06-29
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics and efficacy of EG017 in androgen
receptor-positive, estrogen receptor-positive, and human epidermal growth factor
receptor-2-negative patients with advanced breast cancer.